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Abstract

Biomineralization is the process by which living organisms synthesize minerals. Some bonerelated proteins, such as bone sialoprotein (BSP), have been found to enhance biomineralization,
while others, including osteopontin (OPN), act as inhibitors of this process. Dynamic light
scattering was used to investigate the effect of several native and recombinant proteins and
peptides on the formation and growth of hydroxyapatite (HA) crystals from solutions of Ca2+ and
PO43- ions. We studied two isoforms of OPN, the OPN-derived peptides P0, P3, OPAR and
pOPAR, and recombinant BSP. X-ray diffraction was used to identify the precipitate as HA
crystals. Native OPN inhibits the nucleation of HA crystals, while recombinant OPN strongly
inhibits their growth. Among the peptides studied, the non-phosphorylated P0 weakly inhibits
HA growth, while P3, which has three phosphates, is a potent inhibitor of HA nucleation. OPAR
is found to moderately inhibit nucleation, while its phosphorylated isoform pOPAR more
strongly inhibits the nucleation of the HA crystals as well as having a small effect on their
growth. This work confirms that phosphorylation of OPN is essential to its capability to prevent
mineral growth. Our results show that for high enough ion and protein concentrations, rBSP
inhibits the nucleation of HA, while there is some evidence that it enhances nucleation at very
low protein concentrations
.
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Chapter 1: Introduction and Literature Review
1.1 Biomineralization

Living organisms are capable of controlling the nucleation, growth and morphology of inorganic
crystals within mineralized tissue. This process is called biomineralization. The geological
record indicates that biomineralization has existed in some form for 3.5 billion years and that
skeletal development first took place during Cambrian explosion [1]. Biomineralization occurs
not only in the five animal kingdoms [2] but also in many plant species. Mollusk shells consist of
two kinds of calcium carbonate (CaCO3), argonite and calcite [3]. Hydroxyapatite
(Ca10(PO4)6(OH)2) is the major mineral component of mammalian bones and teeth and it makes
up approximately 65% of their structure by weight [4], while plants are able to synthesize
minerals such as calcium oxalate (CaC2O4) within their roots, leaves, stems and flowers as well
as in fruits and seeds [5,6,7].
Minerals that have been made biologically contain organic as well as mineral components. They
are produced under unusual conditions that are far from equilibrium, so the size, shape and
crystallinity of biominerals are often very different from those of equivalent minerals formed by
abiotic processes [5,8].
Precise biochemical balancing of the biomineralization mechanism by protein inhibitors or
nucleators is needed to prevent ectopic calcification or undesired mineral formation in soft
tissues. Biological fluids like blood and urine are supersaturated with a variety of mineral salts,
but regulatory proteins and low molecular weight inhibitors like citrate and pyrophosphate are
responsible for preventing the minerals from coming out of solution [9]. A deficiency of the
appropriate inhibitors of biominerals can lead to precipitation, resulting in pathological
deposition such as arterial plaque and kidney stone [10].
Bone is a type of rigid connective tissue which serves to provide mechanical support for the body
and to protect some organs, including the brain and spinal cord. Bone plays a role in the
regulation of Ca2+ and PO43- ions in the body because it is a reservoir of these ions [11]. Cells in
1

the bone, including osteoblasts, osteocytes and osteoclasts have responsibility for remodeling the
extracellular matrix (ECM), which provides structural support and is important for maintaining
bone health. The organic extracellular matrix of bone consists of 90% type I collagen, while the
remainder is non-collagenous proteins such as bone sialoprotein (BSP) and osteopontin (OPN).
Type I collagen acts as a scaffold for the tissue, whereas the non-collagenous proteins, including
the members of the SIBLING family of proteins discussed in Section 1.3, are responsible for the
modulation of crystal nucleation, growth and orientation [12]. Hydroxyapatite that is formed on
this scaffold is oriented along the long axis of the collagen fibers. It exists in bone and teeth as
well as in pathological calcifications such as kidney stones and arterial plaque. Abiotic
hydroxyapatite can be found in the form of a monoclinic crystal prism and hexagonal crystals at
temperatures below and above 250°C respectively, while biological HA forms hexagonal crystals
[13].

1.2 Crystal Nucleation and Growth

Many biomineral products precipitate from an initial solution phase and are either completely
crystalline or include crystalline components, so an understanding of the physical principles of
crystallization from solutions is important.

1.2.1

Nucleation

The process by which a crystalline phase first develops in a saturated solution is termed
nucleation. Nucleation happens via the formation of small crystal nuclei in the large volume of
the solution. The solution is metastable, which means that the formation of crystals involves
passage over a free energy barrier. Nucleation of crystals from solution can occur by two
processes: heterogeneous nucleation and homogeneous nucleation. The former happens in the
presence of a foreign substrate or surface that reduces the energy barrier. The formation of
biominerals mostly begins by heterogeneous nucleation. In homogeneous nucleation, on the
other hand, crystal nuclei spontaneously form in the absence of any impurities [14].
2

When a solution of ions is supersaturated, ionic clusters of a critical size can form spontaneously
and homogeneous nucleation occurs. The surface free energy of the solid-liquid interface,
, and the energy released by the formation of bonds within the cluster,

,

determine the total free energy of nucleation associated with the formation of the cluster. The
total change in free energy associated with the formation of the crystal is

(1.1)

where

and

are given by

(1.2)

and

(1.3)

In the above equations, r is the radius of the cluster, σ the free energy per unit surface area, Δu
the molar energy of crystallization and Vm the molar volume.
Combining Equations (1.1), (1.2) and (1.3) gives

(1.4)

The surface free energy scales as r2 while the drop in bulk free energy scales as r3. This means
that for a small radius cluster, the increase in

is larger than the drop in

, which

results in the energy barrier described previously. The relationship between the radius of the
cluster and its free energy of nucleation is illustrated in Figure 1.1.
The difference between the free energy per molecule of the bulk and that of the surface is
referred to as the interfacial free energy per molecule. The interfacial free energy acts to
destabilize the nucleus, when the radius is smaller than a critical size r*, i.e. when the increase in

3

surface energy associated with increasing the size of the nucleus is larger than the decrease in
bulk free energy, the nucleus is unstable. Typically, such a nucleus will dissolve rather than
grow. As soon as the nucleus gets large enough, however, the decrease in free energy associated
with the formation of the bulk phase becomes high enough that it dominates the increase in the
surface free energy, and increasing the size of nucleus decreases the free total energy of the
system. At the critical size r*, the free energy of the system is decreased whether the nucleus
grows or dissolves [14].

Figure 1. 1: Gibbs Free Energy of Ionic Clusters.

As shown in Figure 1.1, the free energy has a maximum at radius r*. This critical radius can be
found by taking the derivative of

with respect to r and setting it equal to zero. The result is

(1.5)

The formation of clusters with radii below the critical radius r* is energetically unfavorable and
they will dissolve back into the solution. Increasing the concentration of the solution results in a
4

larger number of collisions among particles and hence the clusters which spontaneously form
become larger in size. When the size of a cluster exceeds the critical radius, it will continue to
grow, since its free energy decreases for increasing r. The crystal nucleus is now stable.
The maximum value of the free energy of nucleation

at the critical radius is

(1.6)

is a measure of the activation energy for nucleation and is related to the rate of nucleation
by

(

Here A is a constant,

1.2.2

)

(1.7)

is the Boltzmann constant and T is the temperature [14,15].

Heterogeneous Matrix-Mediated Nucleation

One type of heterogeneous nucleation is matrix-mediated crystal nucleation. In this process,
interactions between the protein matrix and the ions lower the potential barrier for the formation
of critical nuclei. The exact process of this mechanism is not yet fully understood [12,16], but
one postulated mechanism for matrix-mediated crystal nucleation and growth is illustrated in
Figure 1.2. A high-resolution electron microscopy study of the growth of bone minerals showed
that the process of crystal nucleation and growth has four stages [17]. In the first step
(Figure 1.2 (a)), ions are absorbed on the organic matrix scaffold. The second step
(Figure 1.2 (b)) involves the formation of crystal nuclei from the ions, leading to crystal growth
(step 3, Figure 1.2 (c)). Step four (Figure 1.2 (d)) is fusion of crystals. This process is extremely
sensitive to local variations in structure.
In all biomineralization processes, the chemistry of the organic matrix plays a crucial role in the
formation and growth of crystals. This chemistry depends on the amino acid sequence and/or
post-translational modifications of proteins in the matrix. Proteins which have been suggested to
5

act as modulators of crystal formation or growth tend to be highly acidic or contain long
sequences rich in acidic amino acids and phosphate groups [18]. Some of these proteins, such as
bone sialoprotein (BSP), have been found to enhance the process, while others, including
osteopontin (OPN), serve as inhibitors of biomineralization [19,20].

Figure 1. 2: Bone crystal growth mechanism a) ionic adsorption, b) nucleation, c) crystal growth, d) crystal
fusion (adapted from [17]).

1.2.3

Growth

After a stable nucleus forms, it will be free to grow. What is necessary for a crystal to grow is
that more ions bind to its surface than leave it. Binding tends to take place at specific sites on the
surface [14,21]. Steps on the surface of the crystal separate flat terraces at different levels. As
illustrated in Figure 1.3, steps at different positions can be connected by kinks. A molecule
coming out of the solution makes more bonds to neighboring molecules when it attaches to a
kink or at step edges than it does on the flat terraces. Kinks are thus key players in crystal
growth. The rate of the crystal growth scales with the kink density, because the probability of the
molecules leaving the crystal and returning to the solution from the kinks is much less than from
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a complete step edge or a site on the terraces. This implies that the growth rate of a crystal can be
reduced by preventing incoming molecules from reaching kink sites, or increased by roughening
the crystal surface.

Figure 1. 3: Illustration of a kink and a step on a crystal surface. Solute molecules bind at kinks either
directly from solution or after adsorbing and diffusing across terraces.

Organisms are able to control the location and crystallographic orientation of nucleation and the
shape of the growing crystallites. The fact that certain organic compounds are found associated
with biomineralized structures and their observed effect on crystallization kinetics indicate that
these compounds modify the growth stage of minerals in addition to controlling nucleation. In
fact, the complex crystal composites and the particular crystallographic orientations that are
observed cannot be explained without appealing to some form of active control [14].
One of the most remarkable examples of biomineral growth is bone. It is believed that collagen
fibers pack into periodic structures containing rows of small gaps known as "hole zones" 40 nm
in length and 5 nm in width, as illustrated schematically in Figure 1.4. When certain proteins
interact with this structural framework they induce nucleation of mineral within these gaps, while
other proteins regulate the mineral growth process. As the nucleated mineral grows, it expands
beyond the hole zones and develops into plates which enclose the collagen [14].
Collagen itself is believed to have no effect on the nucleation of hydroxyapatite. In contrast,
some noncollagenous proteins found in the organic part of the bone have been shown to bind to
7

HA crystals and influence their growth in vitro [4]. In particular, extracellular matrix
phosphoproteins, which are acidic proteins containing phosphate groups, are known to be
involved in triggering and controlling the growth of HA [20, 22].

Figure 1. 4: A schematic diagram of collagen matrix undergoing mineralization. The hole zones between
collagen molecules act as nucleation sites for HA formation.

The role and action of inhibitory molecules in the biomineralization process is an active area of
research. Molecules like osteopontin [23-25] and Matrix Gla Protein (MGP) [26-28] have been
demonstrated to inhibit both physiological and pathological HA formation and to affect crystal
growth. One possible inhibition mechanism involves the protein binding to an existing crystal
surface to inhibit the further deposition of ions. Another involves preventing the formation of
critical nuclei by binding to and isolating free calcium. In the latter case the inhibitor decreases
the number of nuclei available to grow rather than slowing their subsequent growth [12].

1.3 Proteins

Proteins are large biological molecules consisting of one or more amino acid chains. After
synthesis of the primary sequence, many proteins are modified by the addition of various groups
8

including sugars, phosphates, sulphates, and others. This process, termed post-translational
modification (PTM), is essential for the functional attributes of many proteins including the
proteins that are part of the SIBLING (Small Integrin-Binding LIgand, N-linked Glycoprotein)
family of proteins. Phosphorylation is a major PTM within this family. The SIBLINGs are
major components of the extracellular matrix of bone and dentin, and have important roles in the
mineralization of these tissues. Members of this family include osteopontin (OPN), bone
sialoprotein (BSP), dentin matrix protein 1 (DMP1), dentin sialophosphoprotein (DSPP), and
matrix extracellular phosphoglycoprotein (MEPE). Phosphorylation of OPN is required for its
mineral inhibition capabilities [29,30].

1.3.1

Osteopontin

Osteopontin (OPN) is a highly post-translationally modified phosphoprotein. It has
approximately 300 amino acid residues, and its average molecular mass is approximately 44 kDa
[31]. Since it has a high content of aspartic acid and glutamic acid residues, including a
contiguous aspartic acid sequence, it is strongly negatively charged. The negative charge density
is increased by the post-translational modifications [32]. OPN is one of the most abundant noncollagenous proteins, and is present in all body fluids as well as in a range of tissues including
bone, kidney, lung and uterus. It is involved in a number of physiological processes in addition
to biomineralization, such as cancer metastasis and wound healing [33-35]. Figure 1.5 gives the
amino acid sequence of rat OPN [36]. In this figure, each letter refers to an amino acid. The
twenty essential amino acids are shown in appendix A.
Data from in vitro experiments support the notion that OPN inhibits HA crystal formation,
although its structure is similar to BSP [24]. OPN is abundant in highly supersaturated
physiological fluids and pathological depositions. For instance, it is the main organic constituent
of calcium-oxalate-containing kidney stones [24,32]. OPN is not normally present in blood
vessels, but is expressed in atherosclerotic plaque. It has been shown that OPN is expressed by
soft tissues to prevent dystrophic calcification [24,37].
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Figure 1. 5Amino acid sequence of OPN including the 16 residue signal peptide. Each letter refers to an
amino acid and the numbers in the parenthesis are the position of the residue in the complete amino acid
sequence [36].

In vitro studies have indicated that native OPN, phosphorylated OPN-derived peptides, and
synthetic OPN peptides are strong inhibitors of nucleation [23,24,38,40] and growth [39,40] of
HA crystals. Although the mechanism by which mineral formation and growth are inhibited is
poorly understood, other studies have shown that OPN also inhibits the formation of other
biominerals, such as calcium carbonate [37] and calcium oxalate [41,42]. Hunter and co-workers
found that modification of the glutamic acid and aspartic acid residues reduces OPN's inhibitory
potency on HA formation [38]. Constant composition studies indicate that aspartic acid is a more
effective inhibitor than glutamic acid [38]. It has also been demonstrated that the contiguous
aspartic acid segment of OPN participates in preventing HA crystal growth [20,43].
Modulators of crystal nucleation and growth often have altered activities upon immobilization.
For instance, OPN is a known inhibitor of HA formation in solution [22,23,38], but when
immobilized can induce mineral formation [44]. Phosphorylation plays a key role in OPN's
mineral-modulating activity, with phosphorylated OPN or its related peptides being much more
inhibitory than the non-phosphorylated recombinant peptides [38,45,46]. It has been reported
that the inhibitory potency depends on acidic regions rather than particular chemical groups
[24,39].
de Bruyn et al. applied dynamic light scattering to characterize the mechanism of modulation of
crystal formation. Their investigation showed that both nOPN and p-rOPN, a phosphorylated
version of rOPN, inhibit the nucleation of particles from supersaturated calcium phosphate
10

solution. On the other hand, rOPN, which lacks the phosphorylations of nOPN, acted as an
inhibitor of HA growth but not the nucleation [75].
Molecular dynamics simulations have helped elucidate the inhibition mechanism. Grohe et al.
[30] found that phosphate groups had a significant role in bringing the peptide close to the crystal
surface. They simulated three forms of the same OPN peptide (P0, P1, P3), which have the same
amino acid sequence but different numbers of phosphorylations, interacting with a calcium
oxalate monohydrate crystal. Another group performed simulations on phosphorylated OPN
peptides in the presence of calcium oxalate, and also concluded that phosphate groups are
involved in the inhibition of crystal growth [46].

Table 1. 1: Sequences of OPN-derived peptides used in this work.

Molecular Weight

Peptide Name

Amino acid #

Sequence

P0

220-235

SHESTEQSDAIDSAEK

1733.7

P3

220-235

pSHEpSTEQSDAIDpSAEK

1972.64

65-80

SHDHMDDDDDDDDDGD

1833.60

65-80

pSHDHMDDDDDDDDDGD

1913.58

(g/mol)

OPAR (osteopontin
poly-aspartate
region)
pOPAR

Although phosphorylation of OPN seems to be essential to its capability to prevent mineral
growth, it is not clear whether phosphorylation at particular sites in the protein is needed. In this
thesis, we address this issue by testing some peptides for their effect on HA formation and
growth using dynamic light scattering. The peptides listed in Table 1.1 were studied. P0 and P3
corresponded to amino acids 220-235 of the native OPN protein, or residue 236-251 of the OPN
sequence that includes the N-terminal signal peptide (Figure 1.5). P0 has no phosphorylations
while P3 has three. Similarly, OPAR and pOPAR, while correspond to amino acids 65-80 of the
native OPN protein, were studied. OPAR has no phosphorylations while pOPAR has one.
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1.3.2

Bone sialoportein

BSP is an acidic phosphoprotein which has been shown to be a nucleator of hydroxyapatite
in vitro and capable of binding type I collagen [47,48]. Nucleation activity of BSP was first
shown by Hunter and Goldberg in 1993 [20] in steady-state double-diffusion experiments using
agarose gels. At concentrations of 5.5 mM Ca+2 and PO4-3, no precipitation occurred in the gels
unless BSP was included. X-ray diffraction revealed that the recovered precipitates were HA.

Figure 1. 6: Rat BSP amino acid sequence (adopted from [50]). The amino acid number refers to the position
of the residue in the complete amino acid sequence, 1→ ←1 and 2→ ←2 refer to the first and second polyglutamic acid sequences.

Physiological expression of BSP is essentially restricted to mineralized tissues such as bone,
cementum (the calcified substance covering the root of a tooth), dentin and enamel [49].
Mammalian BSPs contain approximately 314 amino acids, including a 16-residue signal
sequence [47,50]. Figure 1.6 illustrates the amino acid sequence of rat BSP. The molecular
weight of mature BSP extracted from rat bone is 52.5 kDa [51], but there is much variability in
this weight as BSP undergoes a number of heterogeneous post-translational modifications.
Electron microscopy has shown that BSP has a rod-shaped core with an average length of 40 nm
[52]. BSP expression is upregulated at times of first mineral deposition in mineralized tissues.
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Its expression is also associated with pathological calcification. BSP expression has been
observed in breast cancer [53], prostate cancer [54], lung cancer [55] and thyroid cancer [56],
and it has been noted that BSP expression leads to the formation of HA crystals in carcinogenic
tumors of the breast and increased metastasis of the cancer cells to bone [53].
As discussed above, BSP is a modulator of mineral formation in steady-state agarose gels
[20,22]. Analysis of the effect of BSP on HA formation indicated that this activity is associated
with two regions of the protein, each of which consists of a sequence of contiguous polyglutamic acid residues [50,57]. While one domain is more effective than the other, neither is as
potent as the full molecule [58]. BSP also contains several phosphates, which are found mainly
on serine residues. A high proportion of Glu residues (approximately 22% of total amino acids)
plus sulfate and phosphate groups make BSP highly acidic. The phosphorylations play a role in
BSP's ability to nucleate crystal formation, though BSP without PTMs can still promote crystal
formation [50].
Fisher in 2001 [59], Wuttke in 2001 [60], and Tye in 2003 [50] showed by NMR (nuclear
magnetic resonance), circular dichroism and small angle x-ray scattering respectively that BSP
has a loose, flexible structure. In contrast, many other proteins have a stable three-dimensional
structure. The unstructured nature of BSP likely allows BSP to interact with multiple partners
including HA [48], collagen [61], matrix metalloproteins-2 [62] and Factor H [63]. BSP also
contains an integrin-recognition sequence Arg-Gly-Asp (RGD) located near the carboxyterminal end of the molecule [57]. The RGD sequence promotes cell attachment, mediates cell
signaling and has been shown to promote osteoprogenitor cell differentiation into osteoblasts
[20,64].
Molecular dynamics (MD) is a powerful computer-based technique for predicting the
interactions between small molecules at the atomic scale. Since crystals have a repeating 3D
lattice, the interaction between peptides and crystal faces can be studied using MD simulations.
Baht et al. performed MD simulations to investigate the nucleation mechanism of BSP [65].
Bone sialoprotein has two glutamic-acid-rich domains located at residues 42–100 and 133–205.
Baht et al. simulated the regions BSP-(59–74) and BSP-(133–148) interacting with the {100}
crystal face of HA. They found that for phosphorylated BSP-(133–148) every other glutamic
acid is able to interact with the surface of the hydroxyapatite crystal to form an electrostatic
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bond. This binding was less pronounced for non-phosphorylated BSP-(133–148). The
phosphorylated peptide contained a longer, more-extended alternating pattern of bonds. This
difference may explain why nucleation activity is enhanced in the phosphorylated form of the
peptide [65]. Previous work by Tye et al. has shown that rBSP-(42-100), which also contains a
Glu-rich region, does not nucleate HA [50]. Simulations of rBSP-(59-74) revealed that, despite
having sites of phosphorylation, this peptide presented quite a different spatial distribution of
side chains and did not adopt the pronounced alternating structure [65]. This suggests that a
particular sequence of amino acids, in this case poly-Glu, is not the only factor that determines
the nucleation potency of the peptide, and that the peptide structure is also important. On the
other hand, Yang et al. also explored the possible role of BSP in nucleation of HA by molecular
dynamic simulations [66]. Their results indicated that the sequence of poly-Glu residues plays a
key role in the nucleation of amorphous calcium phosphate clusters which develop into
crystalline hydroxyapatite.
Mice lacking BSP are viable and breed normally, but there is a significant bone phenotype in
young animals. It has been noted that there is a decrease in mineralization of cortical bones (the
outer shell of the bone which is dense and contributes about 80% of the human skeleton) and
shortened long bones for 0-4 months mice lacking BSP; however, this is overcome by the time
the animals are 12 months old [67].
In 1996 Hunter et al. reported that in solution studies, BSP at concentration up to 10 μg/ml had
no effect on hydroxyapatite formation [22]. An inhibitory effect of BSP and its peptides on
crystal growth in a system of seeded HA crystals was observed by Stubbs et al. [68].

1.4 Methods for Characterization of Protein Modulation of Mineralization

1.4.1

Steady State

The effectiveness of crystal nucleator and inhibitor proteins is generally assessed using the
steady state method. This makes use of a number of plastic cells containing agarose gels which
are arranged in parallel. Calcium and phosphate solutions are separately pumped into the cells, as
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illustrated in Figure 1.7. Spent solutions are collected in a reservoir connected to the outlet of the
cell. A dialysis membrane separates both solution paths from the agarose gel in the center of the
cell. Ions can diffuse across the membrane into the gel, forming a concentration gradient in the
gel. Protein is premixed with the agarose in solution so it is evenly distributed and the agarose is
then allowed to gel. The effect of the protein on nucleation can be assessed by observing the
protein concentrations at which nucleation of hydroxyapatite takes place. Control experiments
are conducted with no protein present. At the end of the experiment, the gels are examined to
determine the calcium and phosphate content [20]. Although this technique has been used to
determine the nucleation potency of a number of proteins including BSP, BSP-derived peptides,
and other bone-related proteins, it has two major disadvantages. The method is very timeconsuming and requires at least five days to run a single experiment. In addition, it cannot be
used to study the kinetics of the nucleation and growth process, but can only reveal whether or
not mineralization has occurred.

Figure 1. 7: Steady-state agarose gel system [adapted from 20].
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1.4.2

Constant Composition Method

Another commonly used method of assessing the modulating potency of proteins and peptides is
the constant composition method, which examines the effect of proteins on the growth of preseeded HA crystals placed in a solution of calcium and phosphate ions [39]. Figure 1.8 illustrates
this method. Seed crystals are added to a continually mixed, metastable solution of calcium and
phosphate ions at pH 7.40. As the crystal grows, OH- ions are used up, reducing the pH of the
solution. This causes more calcium, phosphate, and sodium hydroxide to be released into the
solution by an autotitrator to maintain the pH at the desired value. This feedback loop ensures
that the composition of the calcium phosphate solution remains unchanged over the course of the
experiment. Dissolution of carbon dioxide in the solution is prevented by bubbling nitrogen gas
through it. The total amount of calcium released by the autotitration system yields a
measurement of the crystal growth and can thus be used to generate titration curves.

Figure 1. 8: Constant composition system.

When inhibitor proteins are added to the calcium phosphate solution, the consequent decrease in
the growth rate of the crystal is revealed through a lower volume of titrant added to the solution.
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Comparison of the growth rate in the presence of the inhibitor at different concentrations with
the results of the control experiment yields the protein's inhibition potency. The constant
composition method is an accurate technique for the measurement of the effect of inhibitors on
crystal growth and has been used to characterize proteins such as OPN [39]. This method is
technically difficult and time consuming and, since it uses seed crystals, it gives no information
on the effects of the protein on nucleation.

1.4.3

Dynamic Light Scattering

Light scattering is defined as the deflection of an incident beam of light by small particles. Lord
Rayleigh pioneered the use of light scattering as a technique to study colloidal systems. When
radiation with a given wave vector is incident on a medium, some of it will be scattered by the
medium. A detector positioned at an angle θ relative to the incident radiation will measure the
intensity of the scattered radiation, I(θ,t). The scattering medium in our experiments is a
suspension of small particles of precipitating calcium phosphate which over time will become
HA. Since the scattering particles diffuse through the medium, I(θ,t) fluctuates over time.
The scattering vector q is the difference between the propagation vectors of the scattered and
incident beams. The magnitude of the scattering vector q is given by

( )

(1.8)

where n0 is the refractive index of the scattering medium and λ0 is the wavelength of the light in
vacuum.
The angular distribution of the intensity of light scattered from a colloidal suspension depends on
the size of the suspended particles, the optical properties of the scatterers (such as their
polarizability and refractive index) and the wavelength of the incident light. In a basic light
scattering setup, one measures the average scattered intensity Is or the energy spectrum of the
time dependent intensity, S(ω). Is contains information about the static properties of the scatterers
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while S(ω) depends on their dynamics. Depending on which of these quantities is measured,
therefore, light scattering experiments are generally classified as either static light scattering
(SLS) or dynamic light scattering (DLS). In SLS, the average scattering intensity is measured as
a function of scattering angle. Static light scattering measurements provide structural information
about the scatterers such as molecular weight, radius of gyration, and shape as well as
information about their spatial ordering [69].
One useful and versatile technique to monitor the effect of proteins on the formation and growth
of hydroxyapatite is DLS. In dynamic light scattering, one measures the time dependence of the
scattered intensity. DLS can be used to acquire information about the effective hydrodynamic
size of the suspended scatterers. Most previous studies of hydroxyapatite crystals growth have
been carried out using constant composition seeded growth, but in 1998 Onuma et al. observed
calcium-phosphate clusters with sizes around 1.0 nm in simulated body fluid using an intensityenhanced dynamic light scattering technique. Their report showed the stability of clusters over
time. Their suggested model for cluster growth was that small calcium phosphate clusters packed
together to form HA crystals [70].
The stable nanometer-sized calcium-phosphate clusters were detected in a solution containing
these ions by DLS by Oyane and co-workers in 1999. They investigated the effect of
concentration and pH of the solution on size distribution. They also showed that the
concentration of clusters decreased when the supersaturation of the solution with respect to HA
was decreased [71]. Omuna et al. also studied the precipitation kinetics of HA using a
continuous-angle laser light scattering technique, and measured the molecular growth units of
HA crystals [72].
Fibroblast growth factor-2 (FGF-2), is important in human hard tissue formation and has been
studied by several groups. Onuma et al. adopted dynamic light scattering to monitor the size
distribution of FGF-2 in solutions and the process of converting amorphous calcium phosphate to
hydroxyapatite [73]. Kamiya et al. also used DLS to study the effect of lanthanum doping on the
size distribution and growth of calcium carbonate crystals precipitating from solution. They
found that the presence of La3+ ions caused the particles to grow slowly [74].
More recently de Bruyn et al. applied dynamic light scattering to characterize the mechanism of
modulation of crystal formation. To evaluate the effect of PTMs, three isoforms of OPN –
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nOPN, rOPN and p-rOPN – were examined. Their investigation showed that both nOPN and a
phosphorylated version of rOPN, p-rOPN, inhibit the nucleation of particles from supersaturated
calcium phosphate solution. On the other hand, rOPN, which lacks the phosphorylations of
nOPN, acted as an inhibitor of HA growth but not the nucleation [75].
The effect of matrix gla protein (MGP) peptides on the in vitro formation of HA was also
investigated by DLS by Goiko et al. [27]. MGP is a phosphorylated and γ-carboxylated protein
which prevents the deposition of HA in the walls of blood vessels and kidney. To distinguish the
effect of phosphorylation and γ-carboxylation on HA nucleation, MGP-derived peptides
containing these modifications were compared to unmodified peptides. Their results indicated
that the inhibitory effects on nucleation were dependent on these modifications, and that γcarboxylated groups, similar to phosphorylation, enhances inhibitory activity [27].

1.5 Purpose of this Thesis

The details of the process of biomineralization are complex and not completely understood. It is
known that certain proteins play key roles in both the initial nucleation of biomineral crystals,
and in the regulation of their growth. Some have been observed to enhance nucleation and/or
growth while others act as inhibitors. Controlled biomineralization is vital for mammalian life,
and unregulated mineralization can lead to pathological deposition, causing serious medical
diseases. There is, therefore, considerable motivation for characterizing and understanding the
process of biomineralization, and in particular the role of protein on nucleation and growth
regulation.
This project began with the goal of studying the effect of BSP on both nucleation and inhibition.
Previous work by Hunter et al. in 1993 [20] and Baht et al. in 2008 [47] demonstrated BSPmediated nucleation of HA using agarose and collagen gel-based systems, respectively. Dynamic
light scattering provides an alternative method of investigating the kinetics of nucleation and
growth of hydroxyapatite crystals in the presence of bone-related proteins or synthetic peptides.
Based on our group's success at studying inhibition of mineral formation using dynamic light
scattering [27,75], we initiated DLS studies to characterize early nucleation events mediated by
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BSP. Such results would have provided valuable insight into the nucleation process in
biomineralization. However, we had difficulty in finding the correct conditions to study
nucleation, so this study evolved to focus on inhibition of mineral formation.
The present work uses dynamic light scattering to characterize the inhibitory effects of BSP,
OPN, and OPN-derived peptides on hydroxyapatite formation and growth. To examine the
effects of phosphate groups, both phosphorylated (P3 and pOPAR) and non-phosphorylated (P0
and OPAR) peptides were studied. The goal of this study is to help elucidate the process of
biomineralization. Ultimately, understanding of this process could lead to the development of
peptide therapies to control pathological calcifications that result from the breakdown of the
body’s natural biomineralization regulatory system.
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Chapter 2: Methods
2.1 Dynamic Light Scattering

2.1.1

Theory of Dynamic Light Scattering

In dynamic light scattering, laser light is scattered by a collection of suspended particles, and the
intensity of scattered light is measured at a particular angle with a photomultiplier detector
(Figure 2.3). In a colloidal suspension, the motion of the particles is random and is due to
Brownian motion. The total scattered electric field at the detector is the superposition of the
scattered fields due to all of the particles. In the scattering volume, which is the volume that is
both illuminated by the incident beam and observed by the detector [76], the positions of the
particles vary in time, so the phase of each scattered wave arriving at the detector fluctuates in
time, and E(t), the total scattered electric field at the detector, also fluctuates. This in turn causes
fluctuations in the intensity, which is defined as

(2.1)

where t is the time. These fluctuations in the scattered intensity are the key concept of DLS
experiments. DLS involves measuring the fluctuations in the intensity of the scattered light and
analyzing them to the extract information. The time scale of these fluctuations depends on the
size of the diffusing particles [76], so they can be analysed to calculate the average size of a
particle diffusing in solution. Small particles diffuse more quickly, and so cause a rapidly
fluctuating signal, whereas larger particles diffuse more slowly, resulting in more slowly varying
fluctuations. Figure 2.1 shows a schematic example of an intensity-time plot for small and large
particles.
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Figure 2. 1: Left: A schematic illustration of the fluctuations in scattered intensity observed for scattering
from large and small size particles, Right: Correlation functions for large and small size particles.

It should be emphasized that the fluctuations in the scattered intensity do not result from changes
in the number of particles in the scattering volume, but from changes in the position of the
scatterers. We can get quantitative information out of these fluctuations by examining the decay
of their autocorrelation function. The intensity autocorrelation function
correlation between scattered intensity at a given time t and a later time

shows the
. In order to get

good statistics, this comparison is normally made at many different values of t and averaged. If
one denotes the scattered intensity at an arbitrary time by

and that at a later time

by

, the autocorrelation function is

〈

〉

(2.2)

Here, the angle bracket represents an average over time. When τ=0 the two signals are the same
since the particles have not moved from their initial position and the correlation is high. If the
sampling time interval

is very large, there is no correlation between the pairs of sample

intensities and the above equation becomes
〈

〉
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〈

〉

(2.3)

In our experiment, a digital correlator takes the digitized photo-count measured by the detector,
which is proportional to

, and then computes the correlation function. This function then is

normalized by the value of the correlation function at long times,
correlation function of the scattered intensity is referred to as

〈

electric field,

〉

(2.4)

is related to the autocorrelation function of the

, by the Siegert relation [77]

(

where

and is given by

〉
〈

If the scattering is a Gaussian process,

. The normalized

)

(2.5)

is a constant that depends on the size of the detector and the details of the optics of the

experimental set up. If the particles are spherical, monodisperse, and undergo Brownian motion,
the autocorrelation function of electric field,

, decays exponentially with delay time:

(2.6)

where D is the translational diffusion coefficient. One can find the hydrodynamic radius, which
is the quantity of interest in the present work, from D using the Stokes-Einstein relation,

(2.7)
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Here

is the Boltzmann constant,

is the absolute temperature, and

is the viscosity of the

solution. If the scattering particles are not spherical, DLS measurements provide the apparent
hydrodynamic radius of the particles being examined. If they are polydisperse,

can be

expressed as an integral over a distribution of decay rates, from which the distribution of sizes
can in principle be determined [69,77].

Figure 2. 2: A typical example of autocorrelation function for different-sized particles. The curves are fit to
an exponential decay. The fitted values for the radii are a=2.5 nm, b=54 nm, c=214 nm and d=422 nm. [69].

Figure 2.2 depicts the dependence of the electric field correlation function,
interval

, on time

for nanoparticle scatterers with different sizes. A line has been fitted to data by

assuming a single exponential decay. From the figure we can infer that as the size of the particles
becomes larger, the decay of the correlation function shifts to a longer time. The average
hydrodynamic size of particles can be roughly evaluated by using this shift.
In this thesis, the sample studied is a suspension of small calcium phosphate crystals
precipitating from solution. Measurement of the intensity autocorrelation function as a function
of time allows us to follow the changing hydrodynamic radius of the crystals as they grow.
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Moreover, the average scattered light intensity can be computed as a function of time, allowing
for at least a qualitative measure of the concentration of scatterers. As a result, DLS not only
allows us to assess the effect of the proteins on the growth rate but also on the nucleation of
hydroxyapatite crystals.

2.1.2

Dynamic Light Scattering Experiment

The effects of proteins on the nucleation and growth of crystals can be studied using dynamic
light scattering (DLS). This technique is very effective for measuring the sizes of small particles
as well as for studying protein-protein interactions. It has also been extensively used to examine
the conditions that affect protein crystallization through assessing the sample homogeneity
[70,78,79]. DLS has been used to study the full native and recombinant OPN protein [75], but it
has not been used to study BSP.
Our DLS experimental set-up is schematically depicted in Figure 2.3. The light source is a HeNe
laser with a wavelength of 632.8 nm and power of 22 mW. A CGS-3 compact goniometer
system manufactured by ALV-GmbH was used to perform the scattering measurements. A
photomultiplier detector is positioned on one arm of the goniometer, and can be rotated to
measure the scattered light intensity at angles ranging between 12° and 155°. The
photomultiplier signal is passed to an amplifier, and the digitized output is received by a digital
correlator which calculates the intensity autocorrelation function,

, in real time. The

intensity autocorrelation function is then sent to a computer along with the intensity-time data. A
MATLAB program written by Dr. de Bruyn, which will be discussed below, performs curve
fitting on the autocorrelation function to determine the distribution of hydrodynamic radii of the
scatterers.
The experiments described in this thesis were all performed at a scattering angle of 90°. The
samples were placed in a clean cylindrical cuvette with a radius of 5 mm and made of optical
quality glass. The cuvette is positioned in a chamber at the center of a circular vat filled with
toluene. Since the refractive index of toluene is close to that of the glass, this minimizes stray
scattering from the surface of the cuvette. The temperature of the toluene bath was kept constant
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at 25°C by a temperature controlled circulating bath. The measurements for a given
concentration of protein or peptide were carried out over a 40 minute period. The intensity
autocorrelation functions and mean scattered intensity were calculated from the accumulated
data every 30 seconds.

Figure 2. 3: The experimental set up of the light scattering instrument.

2.1.3

Data Analysis

Because of the random motion of the scattering particles, the autocorrelation function of
scattered electric field,

, will decay as τ increases. The hydrodynamic radius of the

scatterers, which is the radius of a sphere that would have the same average diffusion constant as
the scattering particles, is calculated from its decay rate. For a system of monodisperse scatterers,
decays exponentially with delay time. In our experiment, we have polydisperse
scatterers, so

will not have a simple exponential decay. As discussed in [70,77] the first

two terms of a cumulant expansion for

are

̅
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(

)

(2.8)

where ̅ is the mean relaxation rate of
field autocorrelation function

, and

is its second moment. The electric

is related to

by Equation (2.5), which, using

Equation (2.8) can be written as

̅

(

)

Here the baseline, B, is approximately one, but varies due to noise. We determined ̅ and

(2.9)

from

the measured intensity autocorrelation function using a standard non-linear least-squares fitting
routine. Once ̅ and

were computed from the fits, the mean hydrodynamic radius, ̅ , was

calculated using Equations (2.6) and (2.7) as

̅

We used

and

̅

(2.10)

, for the refractive index and viscosity of water at

25°C.
The standard deviation of the Gaussian size distribution is

√
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̅
̅

(2.11)

2.2 Identification of Precipitates

The crystals precipitated in our experiments were extracted from the solutions and identified by
X-ray diffraction. Details of this technique and the method for harvesting the crystals are
described in this section.
2.2.1

X-ray crystallography

X-ray crystallography is a powerful and non-destructive technique for determining the crystal
structure of many kinds of materials, including solid crystals, powders, and biological
macromolecules such as proteins.
X-rays are electromagnetic radiation with energies above ultraviolet light and below gamma
rays. The wavelengths of X-rays are in the range 0.1-100 Å and their energy is between 120 keV
and 0.12 keV.

2.2.2

X-ray diffraction from a crystal: Bragg’s Law

A crystal is composed of periodic planes of atoms. The planes are indexed by a set of integers
indicating their direction. Atoms in each plane scatter incident X-rays. If every atom scatters Xrays as shown in Figure 2.4, then constructive interference will be observed at certain angles.
The light waves constructively interfere when they are exactly in phase. Assuming that the
incident waves 1 and 2 in Figure 2.4 are in phase when emitted from their source, then the
condition for them to interfere constructively after scattering is that the additional distance 2x
traveled by wave 2 is equal to an integer number of wavelengths. Since

(2.12)
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where d is the distance between the planes and θ is the angle between the incident X-ray and the
plane, a diffraction peak is observed when

(2.13)

This equation is known as Bragg’s Law. As seen in Figure 2.4, the angle between the incident
and diffracted beams is 2θ. Bragg’s law is derived assuming that the atoms are exactly above
each other on the planes, but in fact, they can be located anywhere on the planes [80,81,90].

Figure 2. 4: X-rays scattering from two parallel planes. S0 indicates the incident X-ray beam and S1 the
diffracted beam [81].

2.2.3

Crystal Preparation

The amount of precipitate formed in one 1.8 ml sample tube is very small. Roughly 1 mg of the
precipitate is needed for X-ray diffraction analysis, so several reaction mixtures in tubes were
prepared in parallel to obtain sufficient material for analysis.
The precipitation was allowed to take place for 40 minutes, the same length of time as the DLS
experiments. The solutions from all of the test tubes were then transferred to microfuge tubes and
centrifuged at 8000g for 2 minutes. The supernatant liquid was removed using a pipette, and the
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crystals were washed with 100 μl or more pH10 water. pH10 water is a mixture of 10%
ammonium hydroxide and deionized water and is used to stop the reaction between calcium and
phosphate ions. The tubes were shaken gently to wash the crystals well and centrifuged again for
2 minutes. The pH10 water was then removed and 100 μl or more 100% ethanol was added to
the tubes. Once again, the microfuge tubes were gently tapped, and then all the contents were
combined into a single tube and centrifuged for 2 minutes. The ethanol was removed and the
collected precipitant dried at room temperature and stored in a dessicator.
The precipitate was analyzed with a Bruker D8 Discover micro X-ray diffractometer using
Cobalt Kα radiation (1.78897 Å) (performed by Prof. Roberta Flemming and Michael Bramble
from Western’s Department of Earth Sciences). The crystal structure was identified by
comparing the measured diffraction pattern with catalogued standard patterns from the
International Centre for Diffraction Data (ICDD) database.
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Chapter 3: Materials
3.1 Preparation of Solutions

A significant amount of time was spent to find the appropriate concentrations of reagents and
preparation technique that resulted in reproducible results.
For our studies of nucleation and inhibition, four 100 ml stock solutions of sodium chloride
(NaCl), sodium

phosphate dibasic (Na2HPO4), tris

(hydroxymethyle)

aminomethane

(C4H11NO3), and calcium chloride (CaCl2) with concentrations of 2.0M, 0.25M, 1.0M, and 0.5M
respectively, were prepared using deionized water. All of the chemicals were purchased form
Sigma-Aldrich Inc and had purities of above 99%. To remove bacteria and minute particles, the
solutions were filtered through 0.2 μm membrane filters (Nalgene). The stock solutions were
kept in clean, autoclaved bottles. Stock solutions were normally made fresh every two weeks to
ensure reproducible results.
Three 50 ml working solutions were prepared daily from the stock solutions. The working
solutions were: a calcium solution consisting of 12 mM CaCl2, 150 mM NaCl, 18.75 mM Tris; a
phosphate solution containing 7.5 mM Na2HPO4, 150 mM NaCl, 18.75 Tris; and a Tris solution
with 150 mM NaCl and 18.75 mM Tris. The pH for each solution was adjusted to 7.40 by adding
dilute NaOH or HCl. This pH and the NaCl concentration were chosen to mimic in vivo
conditions. Since any contaminants could scatter light and skew the results, the solutions were
filtered a second time through fine 0.02 μm Whatman syringe filters directly into sterile BD
falcon tubes. These final working solutions were only used on the day of preparation to ensure
reproducible results.
In order to find suitable control conditions for hydroxyapatite crystal formation and growth, we
prepared and tested solutions with different concentrations of calcium and phosphate ions. The
rate of crystal growth should be slow enough to allow time to perform a measurement, but fast
enough that a significant change in the crystal size took place over the forty-minute duration of
the experiment. The growth rate is very sensitive to small changes in pH and temperature, so we
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had to slightly change the concentration of Ca2+ and PO43- for experiments performed on
different days. Each day, the selected control concentrations of ions were then used for all
experiments on that day.
Tables 3.1 and 3.2 give the Ca2+ and PO43- concentrations and volumes that were used in each
protein or peptide-containing run. All concentrations of a given protein or peptide were tested on
the same day. For each run, the ratio of Ca2+ and PO43- was maintained at 1.60, which is the most
favorable value for hydroxyapatite formation.

Table 3. 1: The concentration and volume of Ca2+ and PO43- solutions used for protein runs.

Protein

[Ca2+] (mM)

VCa (μl)

[PO43-] (mM)

VPO4 (μl)

nOPN

5.800

870

3.625

870

rOPN

5.400

810

3.375

810

rBSP

5.200

780

3.250

780

rBSP

5.400

810

3.375

810

Table 3. 2: The concentration and volume of Ca2+ and PO43- solutions used for peptide runs.

Peptides

[Ca2+] (mM)

VCa (μl)

[PO43-] (mM)

VPO4 (μl)

P0

5.460

820

3.416

820

P3

5.400

810

3.375

810

OPAR

5.660

850

3.541

850

pOPAR

5.730

860

3.583

860

In all cases, a total volume of 1.8 ml was used. The volumes of calcium and phosphate solutions
given in the Tables were combined with sufficient Tris solution to give the required total volume.
When an aliquot of dissolved peptide in Tris buffer was added to the solution the volume of Tris
solution was reduced accordingly. The required volume of calcium solution, Tris buffer and the
protein or peptide under study were combined in a 5 ml borosilicate glass tube, and then the
phosphate solution was added to initiate the nucleation of HA. The glass tube was gently
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inverted three times to mix the solutions, and was then cleaned and immediately put in the
sample chamber of the light scattering instrument.

3.2 Proteins and Peptides Preparation

To investigate the role of phosphorylation in biomineralization process, native and recombinant
proteins and synthetic peptides containing 0, 1 and 3 phosphate groups were used. The proteins
studied were native osteopontin (nOPN), recombinant osteopontin (rOPN) and recombinant bone
sialoprotein (rBSP). These proteins were prepared in-house. For example, nOPN was extracted
from rat bone and then purified by H. Chen using the protocol described in [82]. Rat nOPN was
shown to have a mass of 37600 g/mol, and contained approximately 10 phosphate residues per
molecule. Furthermore it is glycosylated and sulfated [75]. Recombinant rat osteopontin,
containing a short His-tag for purification purposes, was expressed by BL-21 bacteria and
purified [32]. It has a mass of 36046 g/mol and contains the same polypeptide chain as nOPN but
without the post-translational modifications. Similarly, rBSP was expressed and purified by
H. Chen as described in [50]. One of the serine amino acid of the rBSP used in these studies was
substituted by alanine. The rBSP has a molar mass of 34780 g/mol [12].
We also studied the peptides P0 and P3, which correspond to amino acids 220-235
(SHESTEQSDAIDSAEK) of rat OPN and contain zero and three phosphates, respectively, and
OPAR and pOPAR, which include amino acids 65-80 (SHDHMDDDDDDDDDGD) of rat bone
OPN, and which contain zero and one phosphate, respectively.
Phosphorylated and non-phosphorylated peptides were synthesized by a batch method and
purified by Y. Liao as described in [29,30,39]. The final peptide preparations were >98% pure.
The peptide masses were obtained using mass spectrometry and are presented in Table 1.1.
All the proteins and peptides were stored at -20°C as pre-weighed freeze-dried aliquots. For the
experiments one or more tubes of protein were dissolved into a volume of filtered 0.05 M Tris
buffer solution at pH 7.4 to achieve a concentration of 1 μg/μl. The amount of protein solution
used in individual experiments is indicated in the Results. To prevent degradation of the
dissolved protein aliquots they were kept on ice until used.
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Chapter 4: Results
4.1 Dynamic Light Scattering Results for Control Experiments

Prior to doing each set of experiments we carried out control experiments with no protein or
peptide added to the calcium phosphate solution. The control experiments provide a baseline for
the nucleation and growth of hydroxyapatite crystals in the absence of protein or peptide. They
also help us to confirm the consistency of the results. Control solutions were prepared using the
method described in section 3.1 and Table 3.1 and Table 3.2. The intensity autocorrelation
function for one of the control experiments is plotted in Figure 4.1. The red line is a fit to
Equation (2.9).

Figure 4. 1: Intensity autocorrelation function for a typical control experiment. The fit to Equation (2.9) is
shown as a red curve.
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Having determined ̅ from the fit, we can find the mean hydrodynamic radius from Equation
(2.10) as described above.

Figure 4. 2: A) The mean scattered light intensity, , and B) the mean hydrodynamic radius of the particles,
̅ in the absence of protein.

Figure 4.2 (A) shows the time dependence of the averaged scattered light intensity,

, as well as

the standard deviation of the fluctuating intensity for a typical control experiment. Note the mean
value, Im, is much smaller than these error bars. The averaged scattered light intensity is given in
terms of the photon count rate detected by the photo multiplier. During the first two minutes of
the experiment, the data are not reliable because of fluid motion due to mixing and placing of the
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sample in the chamber. Over the duration of the measurements, the scattered intensity increases
steadily and relatively linearly as the calcium phosphate precipitates. The scattered light intensity
depends in a complex way on the size of the scatterers as well as their concentration [75,76].
For the range of particle sizes relevant here,

is approximately proportional to particle

concentration and to ̅ [76,83]. Therefore, the size of the scatterers has more impact on
than their concentration.
The dependence of ̅ on time for the same control run is shown in Figure 4.2 (B). In this Figure,
the error bars, σr, represent the standard deviation of the Gaussian distribution of particle sizes
obtained from the fit, as described in Equation (2.11). As above, the uncertainty on ̅ is much
smaller than these error bars. At the beginning of the experiment ̅ is about 120 nm, and it
grows to approximately 700 nm at forty minutes. The width of the size distribution is relatively
broad and becomes larger as time passes. The growth rate of the precipitating particles is given
by the slope of the plot of ̅ versus time, and is higher at the beginning of the experiment than at
the end.

4.2

X-ray Diffraction Result for Control Experiments

The protocol described in section 2.2.3 was used to recover crystals from a control experiment.
The results of the X-ray diffraction analysis are shown in Figure 4.3. The diffraction pattern of
the precipitate that formed in the control experiment matched well with the ICDD card # 01-0730293 for hydroxyapatite. The intensity of the Debye rings (results not shown here) is uniform,
implying that the crystals are fine grained. The narrow diffraction lines, illustrated in Figure 4.3,
demonstrate that the crystals are well-formed. From the width of the peaks the size of the crystals
is estimated to be 200 nm. This is slightly less than the value of ̅ measured with DLS. The red
and green lines shown in the figure are expected diffraction peaks for hydroxyapatite and
calcium phosphate hydrate respectively. The measured diffraction pattern is very similar to both,
but calcium phosphate hydrate is not expected to form under the conditions in our experiments.
Our crystals were therefore identified as hydroxyapatite.
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Figure 4. 3: X-ray diffraction pattern of precipitate collected from a control experiment compared to
standard spectra for hydroxyapatite (red) and calcium phosphate hydrate (green).

4.3 Dynamic Light Scattering Results for nOPN

We examined the effect of nOPN on HA crystal nucleation and growth. The prepared solution
contained 5.80 mM calcium and 3.63 mM phosphate ions. Figure 4.4 (A) shows the scattered
intensity as a function of time for concentrations of 0, 1, 2, 3, 4, and 8 μg/ml nOPN. These
concentrations correspond to approximately 0.03, 0.06, 0.08, 0.12, and 0.24 μM of nOPN. Here,
the error bars for the scattered intensity indicate the standard deviation of the count rate. Adding
1 μg/ml nOPN notably decreases the scattered light intensity, and as the concentration of nOPN
is increased, the scattered intensity drops further. From Figure 4.4 (B) we can see that the
presence of nOPN causes a delay in nucleation and growth of the particles. The delay times
become larger as the nOPN concentration increases.
Figure 4.4 (B) shows the mean hydrodynamic radius as a function of time for different
concentrations of nOPN. The error bars on the plot of ̅ versus time indicate the standard
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deviation of the distribution of the particle sizes, σr, which is found by fitting Equation (2.9) to
the intensity autocorrelation function. At early times, ̅ remains low and smaller than in the
control experiment. After a delay, it finally starts to grow. Similar to what was observed for the
scattered intensity, the presence of nOPN delays the growth of the particles, with the delay time
becoming larger as the concentration increases. Once the crystals start to grow, they grow faster
than in the control experiment, and eventually, the size of precipitating particles becomes larger
than in the control experiment. In spite of this, the scattered intensity is always smaller than that
of the control experiment. As described earlier, the scattered intensity depends on both the
concentration and the size of the scatterers. Here, in the presence of nOPN, the size of the
scattering particles increases but the scattered intensity remains lower than the control value. We
can therefore infer that the concentration of the scattering particles decreases in the presence of
nOPN. These results imply that nOPN inhibits the nucleation of the HA crystals. Very few
calcium phosphate particles can nucleate when nOPN is added to the solution, but, as
Figure 4.4 (B) shows, after a delay those particles grow faster in the presence of nOPN than in
the control experiment.
Figure 4.4 (C) shows the scattered light intensity as a function of hydrodynamic radius. At a
fixed size of scatterers, Im depends only on the number of scattering particles. For sizes greater
than about 200 nm, the number density of the scattering particles decreases significantly when
protein is added to the solution. For instance, at 400 nm the value of Im for 1 μg/ml nOPN is
smaller than the control value by a factor of five. Overall, the results suggest that nOPN inhibits
the nucleation of HA crystals.
The delay time was found by fitting a straight line to ̅

in a time interval just after it starts to

grow significantly and then extrapolating the fit to ̅

. Figure 4.5 illustrates that the delay

time increases with concentration of protein. The dashed line, which is a linear fit to the data
points, implies that there is a threshold concentration of 0.65±0.47 μg/ml for nucleating HA
crystals in presence of nOPN.
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Figure 4. 4: (A) The mean scattered intensity versus time, (B) The mean hydrodynamic radius of the
scatterers as a function of time, (C) The mean scattered photon count rate as a function of hydrodynamic
radius in the presence of a range of concentration of nOPN added to the calcium phosphate solution.
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Figure 4. 5: Delay time as function of nOPN concentration for the beginning of the crystal growth.

4.4 Dynamic Light Scattering Results for rOPN

We studied the effect of recombinant OPN on the nucleation and growth of hydroxyapatite.
Since rOPN lacks the phosphorylations of the native OPN, comparison of the results of these
experiments with those of section 4.3 should provide information on the role of those
phosphorylations on control of biomineralization.
Figure 4.6 (A) and (B) show the scattered photon count rate and the hydrodynamic radius of the
scatterers in the presence of 1, 3, and 6 μg/ml rOPN. These concentrations correspond to
approximately 0.03, 0.08, and 0.17 μM of rOPN. As in the case of nOPN,

decreases as the

rOPN concentration increases but ̅ behaves differently. ̅ decreases as the concentration of
rOPN increases with minimal apparent growth of particles at high concentrations. As the
concentration increases from 1 μg/ml to 3 μg/ml the hydrodynamic radius drops significantly. At
6 μg/ml rOPN, the highest concentration studied, the particles grow very little over the duration
of the measurement. By the end of the experiment, there is a 94% decrease in the radius of the
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scatterers in the presence of 6 μg/ml rOPN relative to the control measurement. Based on these
observations, we can infer that rOPN strongly inhibits the growth of HA crystals.
The scattered light intensity is plotted as a function of ̅ in Figure 4.6 (C). At small ̅ ,

is

considerably higher in the presence of rOPN than in the control experiment. Thus, we can infer
that at a fixed size of scatterers, the concentration of calcium phosphate particles is larger in the
presence of the protein than in the control solution.
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Figure 4. 6: Precipitation of calcium phosphate solution in the presence of recombinant OPN. (A) Mean
scattered light intensity and (B) Mean hydrodynamic radius as a function of time for different concentration
of rOPN. (C) Mean scattered light intensity as a function of hydrodynamic radiius.
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4.5 X-ray Diffraction Results for nOPN and rOPN

Crystals were also harvested from experiments performed with 1 µg/ml nOPN and 1 µg/ml
rOPN. The measured X-ray patterns are shown in Figures 4.7 and 4.8, respectively. Both
samples have diffraction pattern features that match hydroxyapatite, ICDD card # 01-073-0293.
As in the control experiment, the crystals formed in the presence of the proteins were very fine
grained, as evidenced by broadening of the Debye rings in the powder pattern. Comparison of
the X-ray diffraction patterns of the precipitants formed in the presence of nOPN and rOPN with
that from the control experiment indicates that the patterns are similar, so the crystals formed are
the same in all cases.

Figure 4. 7: X-ray diffraction pattern of precipitate collected from experiments in presence of 1 µg/ml nOPN.
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Figure 4. 8: X-ray diffraction pattern of precipitate collected from experiments in presence of 1 µg/ml.

4.6 Dynamic Light Scattering Results for P0

In vivo and in vitro studies have shown that OPN inhibits the nucleation and growth of HA and
other biominerals and prevents the calcification of soft tissues. However, the nature of the
interaction between OPN and HA is not yet fully understood. We performed experiments on
peptides derived from OPN to investigate the inhibitory effects of particular regions of the
protein. P0 is a non-phosphorylated peptide corresponding to amino acids 220-235 from OPN.
Aliquots of 5, 7, 10 and 15 μg/ml of P0 were added to a solution with ion concentrations of
5.46 mM calcium and 3.41 mM phosphate. These peptide concentrations correspond to molar
concentration of 3.0, 4.0, 6.0 and 9.0 μM, respectively. The results for P0 are presented in
Figure 4.9.
As can be observed in Figure 4.9 (A), increasing the concentration P0 has only a small effect on
the scattered light intensity. For the highest concentration of P0, 15 μg/ml, the average scattered
light intensity at the end of the experiment decreases by 22% relative to the control level.
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Figure 4.9 (B) demonstrates that hydrodynamic radius measured at peptide concentrations of 5,
7, and 10 μg/ml overlaps with the control data. Addition of 15 μg/ml of P0 to the solution causes
the hydrodynamic radius to decrease slightly below the level of the control. These observations
indicate that P0 has a very weak effect on HA formation, and inhibits crystal growth only at very
high concentrations. Figure 4.9 (C) shows the intensity as a function of hydrodynamic radius.
The scattered intensity at a given hydrodynamic radius in the presence of 5, 7, and 10 μg/ml
peptide is slightly below the control experiment, indicating a small decrease in the concentrations
of scatterers. At a concentration of 15 μg/ml, I(t) is slightly higher than in the control run,
suggesting that at very high concentrations of P0, the number density of the calcium phosphate
particles increases by a small amount. Overall, this peptide exhibits a very weak inhibitory effect
on the growth of HA crystals.
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Figure 4. 9: (A) Mean scattered light intensity as a function of time, (B) mean hydrodynamic radius as a
function of time, (C) scattered light intensity as a function of hydrodynamic radius for different concentration
of P0.
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4.7 Dynamic Light Scattering Results for P3

The inhibitory effect of P3, which is a synthetic peptide containing 3 phosphates corresponding
to OPN sequence 220-235, was measured using dynamic light scattering. We added 0.3, 0.5, 1,
2, and 5 μg/ml P3 to a calcium phosphate solution that contained 5.40 mM Ca2+ and
3.37 mM PO43-. The P3 concentrations correspond to approximately 0.15, 0.25, 0.50, 1.0, and
2.50 μM, respectively. In contrast to P0, the inhibitory effect of P3 was observable at relatively
low concentrations.
As illustrated in Figure 4.10 (A), the presence of P3 causes the scattered intensity to drop, with
the count rate becoming lower as the concentration of P3 increases. At the highest studied
concentration of the peptide, 5 μg/ml, the mean scattered light intensity at the end of the
measurement shows an approximate ten-fold reduction relative to the control experiment.
The effect of P3 on ̅ is presented in Figure 4.10 (B). It shows that increasing the concentration
of P3 has no measurable effect on the hydrodynamic radius of HA crystals. For the highest
concentration of P3, the hydrodynamic radius at the end of the experiment decreases by 4.7%
relative to the control level. No delay in crystal growth was observed in the presence of P3.
The scattered light intensity as a function of the hydrodynamic radius is shown in
Figure 4.10 (C). As the figure illustrates, all concentrations of P3 reduce the photon count rate
below the level of the control at any given hydrodynamic radius. The addition of increasing
concentration of P3 resulted in decreased concentration of HA crystals. Altogether, P3 is a potent
inhibitor of HA nucleation.
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Figure 4. 10: (A) Mean scattered light intensity as a function of time, (B) mean hydrodynamic radius as a
function of time, (C) scattered light intensity as a function of hydrodynamic radius for different
concentrations of P3.
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4.8 Dynamic Light Scattering Results for OPAR

We also studied the effects of other OPN-derived synthetic peptides on HA growth. A peptide
corresponding to the Osteopontin Poly-Aspartate Region (OPAR; OPN65-80) was incubated
with a calcium phosphate solution containing 5.66 mM calcium and 3.53 mM phosphate ions.
Figure 4.11 (A) shows the plot of the scattered photon count rate as a function of time in the
presence of different concentrations of OPAR. The OPAR concentrations studied were 0.3, 0.5,
1, 2, 5 and 7 μg/ml, corresponding to approximately 0.16, 0.3, 0.55, 1.1, 2.7, and 4.0 μM,
respectively. Error bars are analogous to those in previous figures. The intensity of the scattered
laser light starts to drop immediately and without any delay as we add OPAR to the calcium
phosphate solution.

increases roughly linearly over the course of measurement and decreases

as the OPAR concentration increases. With 7 μg/ml of OPAR added to the calcium phosphate
solution, the intensity at the end of the measurement was decreased by a factor of six.
Figure 4.11 (B) shows the mean hydrodynamic radius of the particles as well as the standard
deviation of particle sizes. Regardless of the peptide concentrations, the HA crystals grow in a
similar manner. At the beginning of the measurement, the sizes of the particles are more or less
the same for all concentrations. It seems the particles are slightly smaller when OPAR is added,
but the difference from the control is small. The fact that particles have sizes almost the same as
the control solutions combined with their lower value for the scattered intensity, suggest that the
concentration of the particles has decreased in the presence of OPAR. No delay in crystal growth
is observed. These results suggest that the presence of OPAR significantly inhibits nucleation but
not growth. Results for Im as a function of hydrodynamic radius are shown in Figure 4.11 (C). At
small fixed sizes and in the presence of the lowest protein concentration, the particles scatter
light as much as they do in the control experiment. As the concentration of OPAR increases, the
photon count rates decreases. At about 300 nm size, the scattered intensity drops by about a
factor of six for the highest OPAR concentration studied, 7 μg/ml. Since the addition of OPAR to
the calcium phosphate solution decreases the concentration of the precipitant, these findings
suggest that OPAR is a moderate inhibitor of nucleation.
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Figure 4. 11: (A) Mean scattered light intensity as a function of time, (B) mean hydrodynamic radius as a
function of time, (C) scattered light intensity as a function of hydrodynamic radius for different
concentrations of OPAR.
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4.9 Dynamic Light Scattering Results for pOPAR

We also used DLS to measure the size and growth rate of crystals precipitating from a solution
of calcium phosphate ions in the presence of the phosphorylated version of the osteopontin polyaspartate region (pOPAR). We added 0.3, 0.5, 1, and 2 μg/ml pOPAR to a calcium phosphate
solution that contained 5.73 mM Ca2+ and 3.58 mM PO43-. The pOPAR concentrations
correspond to approximately 0.15, 0.26, 0.52, and 1.05 μM, respectively.
The average scattered light intensity is plotted as a function of time for various concentrations of
pOPAR in Figure 4.12 (A). The photon count rate is slightly lower than in the case of OPAR,
however, the overall behaviour is almost the same. Increasing the concentration of pOPAR
decreases the photon count relative to the control measurement.
The effect of pOPAR on the hydrodynamic radius is presented in Figure 4.12 (B). It shows that
the size of the particles in the presence of pOPAR is slightly smaller than in control over the
course of measurement. At all studied pOPAR concentrations, the growth rates of the
precipitating crystals are similar to each other and to the control. Furthermore, no delay in the
growth of these calcium phosphate particles is observed.
The effect of pOPAR concentration becomes more evident if the average scattered light intensity
as a function of hydrodynamic radius is plotted. Figure 4.12 (C) illustrates that at a particular size
of the scatterers,

decreases as the amount of the peptide is increased, meaning that the number

density of the HA particles becomes lower as the pOPAR concentration is increased. In the
presence of pOPAR, few particles form at early times but they grow at the same rate as in the
control experiment. Fewer particles imply that pOPAR reduced the level of nucleation of HA.
Since in the presence of pOPAR the crystals become slightly smaller, pOPAR may also have a
small effect on the growth of the hydroxyapatite crystals.
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Figure 4. 12: (A) Mean scattered light intensity as a function of time, (B) mean hydrodynamic radius as a
function of time, (C) scattered light intensity as a function of hydrodynamic radius for different
concentrations of pOPAR.
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4.10 Dynamic Light Scattering Results for rBSP

It has been proposed that BSP acts to initiate calcification in mineralized tissues [20,47]. To test
this hypothesis, the effect of recombinant BSP on hydroxyapatite crystal formation was
measured using dynamic light scattering. We attempted to find a concentration of calcium and
phosphate ions at which precipitation of crystals does not happen in the absence of rBSP, but did
happen in the presence of rBSP. It was postulated that BSP would cause the spontaneous
nucleation of crystals below the normal threshold concentrations of calcium and phosphate ions.
We studied the effect of adding protein on two solutions with different concentrations of calcium
and phosphate. The first solution contained 5.20 mM Ca2+ and 3.25 mM PO43- and the second
solution contained slightly higher calcium and phosphate ion concentrations: 5.40 mM Ca2+ and
3.37 mM PO43-.
Figures 4.13 (A) and (B) show the scattered intensity and the hydrodynamic radius as a function
of time for precipitation from the first solution for a control experiment and in the presence of 1,
2, 4 and 6 µg/ml rBSP, corresponding to molar concentrations of approximately 0.03, 0.06, 0.12,
and 0.18 μM rBSP. The scattered photon count rate is very low for this solution, indicating a low
concentration of scatterers. As can be observed from Figure 4.13 (A), at an rBSP concentration
of 1 µg/ml, the average scattered light intensity is above the level measured in the control
experiment; at 2 µg/ml rBSP, the scattered intensity is initially lower but becomes equivalent to
the control experiment at 40 minutes. At higher rBSP concentrations, Im is decreased throughout
the 40 minute duration of the experiment. Figure 4.13 (B) shows that for all concentrations
studied, the particles are smaller than in the control experiment. Increasing the concentration of
rBSP decreases the size of the crystals at any given time. This suggests that rBSP at 1 and
2 µg/ml enhance nucleation.
As mentioned above, for a concentration of 1 µg/ml the scattered intensity is higher than the
control value, but the hydrodynamic radius is smaller.

depends on both the size as well as the

concentration of the scatterers. Since Im is higher than the control value for 1 µg/ml, while ̅ is
smaller we can infer that the concentration of the calcium phosphate particles has increased in
the presence of low protein concentration. For concentrations of 4 and 6 µg/ml, few particles are
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detected within the first 1500 seconds of the experiment, and then the particles that do form grow
slowly over the duration of the measurement. At the end of the experiment there is about a fourfold reduction in ̅ for 2 µg/ml rBSP compared to the control, though the scattered intensity is
equivalent. This indicates that the concentration of the particles is increased compared to the
control at 40 minutes, suggesting that at low protein concentration rBSP enhances nucleation.

Figure 4. 13: (A) The mean scattered intensity versus time, and (B) The mean hydrodynamic radius of the
scatterers as a function of time, for experiments in which rBSP is added to the 5.20 mM calcium and 3.25 mM
phosphate solution.
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This experiment was done only once. The results may be affected by small uncertainties in
concentration due to pipetting uncertainties. More trials would be needed to allow a definitive
conclusion. Nonetheless, our data suggest that rBSP enhances nucleation at low concentrations,
while it appears to inhibit growth at 2 µg/ml and higher.
This experiment was repeated with the higher-concentration solution containing 5.40 mM Ca2+
and 3.37 mM PO43-. The measured scattered photon count rate and the size of the particles are
shown in Figure 4.14 (A) and (B). Based on the control data, at these ion concentrations there is
substantial crystal formation in the absence of protein. Experiments were performed with 1, 2, 4,
6, and 8 μg/ml of rBSP added to the solution, corresponding to molar concentrations of
approximately 0.03, 0.06, 0.12, 0.18, and 0.23 μM.
Adding 1 μg/ml rBSP to the solution does not have a significant effect on the scattered light
intensity. For higher concentrations, however,

decreases as the rBSP concentration increases.

The scattered light intensity has almost the same value for the two highest concentrations
studied.
The effect of rBSP on calcium phosphate precipitation at supersaturated concentrations of
calcium and phosphate is similar to that observed with the addition of OPN, though the inhibition
is markedly less. At 1 μg/ml rBSP, there is little change in
experiment, but at higher concentrations of rBSP,
reduces

compared to the control

decreases (Fig 4.14 (A)). At 8 µg/ml, rBSP

by 50% whereas 8 µg/ml of nOPN (Figure 4.4 (A)) and 6 µg/ml of rOPN

(Figure 4.6 (A)) reduces

by 90% or more. Increasing the concentration of rBSP appears to

cause a short delay in the increase of the scattered intensity, but, again, this effect is much less
than that observed with both isoforms of OPN.
Similar to what is observed for nOPN, once the particles begin to grow, the hydrodynamic radius
increases more quickly in the presence of the protein than in the control experiment. After 1000
seconds, the precipitating particles are actually larger than in the control experiment. However, it
is not clear that rBSP causes a true delay in nucleation, since particle formation is observed at
early times for all concentrations of rBSP tested. In contrast, the data for nOPN showed a more
distinct absence of particle formation at early times.
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To better distinguish the effect of rBSP on the HA crystal concentration, the scattered light
intensity is plotted as a function of mean hydrodynamic radius in Figure 4.14 (C). At small
values of ̅ , for high concentration of rBSP

is higher in the presence of the protein

suggesting that rBSP promotes the formation of small particles. For ̅ greater than about
300 nm, however, the scattered light intensity is lower in the control experiment, suggesting
fewer particles of larger size in the presence of the protein. The ̅ vs. time data show that these
particles grow faster than in the control experiment. The scattered intensity initially decreases as
rBSP concentration increases, then appears to increase again for the highest rBSP concentrations
studied. This will be discussed further in the Chapter 5.
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Figure 4. 14: (A) The mean scattered intensity versus time, (B) the mean hydrodynamic radius of the
scatterers as a function of time, (C) the mean scattered intensity as a function of hydrodynamic radius for
rBSP added to a solution containing 5.40 mM calcium and 3.37 mM Phosphate.
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Chapter 5: Discussion

Dynamic light scattering is a well-established, versatile and non-invasive technique which can
provide information about the size distribution of the scatterers and particle populations in real
time. Dynamic light scattering has long been a powerful tool for studying a wide range of
phenomena. It offers an alternative approach to the study of the protein-biomineral interactions.
In the work described in this thesis, we have used DLS to investigate the kinetics of the
nucleation and growth of crystals from a supersaturated solution of calcium and phosphate ions
in the presence of bone-related proteins and synthetic peptides. Unlike the traditional methods
described in sections 1.4.1 and 1.4.2, DLS permits us to monitor the initial stages of the
nucleation process and determine the size and relative concentration of the growing crystals as a
function of time. This allows an immediate assessment of the effect of proteins on mineralization
and nucleation.
BSP has been shown previously to act as a nucleator of HA crystallization [20,47]. We attempted
to study this phenomenon using DLS, but found that studying nucleation is not as simple as
studying inhibition. It was particularly difficult to find a threshold ion concentration at which
adding BSP triggers the formation of HA. We attempted to find the critical point at which CaPO4
will not precipitate in the absence of BSP, but at which addition of BSP will result in biomineral
nucleation. We modified the experimental solution changing the concentrations of salts and
buffers. Unfortunately, we were unable to find a concentration at which BSP unambiguously
caused nucleation. Poly glutamic acid, which has also been shown to be a potent driver of
nucleation [84], was also not observed to induce nucleation in this system. Because of this we
decided to change our approach and did not focus on the nucleation effects of BSP below the
threshold for HA formation, but rather studied inhibitory proteins and peptides above the
nucleation threshold.
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5.1 Osteopontin

Our results show that both native and recombinant OPN inhibit the precipitation of calcium
phosphate particles from solution. Native OPN delays the nucleation of particles and causes a
significant decrease in particle concentration compared to the control experiment. However, the
few calcium phosphate particles that do nucleate grow faster than in the control experiment. At
the end of the measurement, the mean particle size is greater than 1 μm. The time at which ̅
starts to grow significantly increases linearly with the concentration of nOPN. In the presence of
OPN, the scattered light intensity is significantly below that of the control experiment, indicating
that the number density of scattering particles has decreased. We can therefore conclude that the
presence of nOPN strongly prevents the formation of the particles. This could have occurred in
two ways: the nOPN could inhibit the nucleation of calcium phosphate particles, or it could
prevent small nucleated clusters from growing large enough to be observed by the DLS detector.
In the presence of rOPN, both the scattered light intensity and the size of particles decrease.
Moreover, the particles grow more slowly than in the absence of protein. In contrast to the case
of nOPN, rOPN does not cause any noticeable delay in early precipitation. We can thus infer that
rOPN does not have any effect on the nucleation of calcium phosphate particles but it slows their
growth.
In vitro studies have indicated that OPN and natural and synthetic OPN peptides are strong
inhibitors of nucleation [23,24,38] and growth [39] of HA crystals. Although the mechanism by
which mineral formation and growth are inhibited is poorly understood, other studies have
shown that OPN also inhibits the formation of other biominerals, such as calcium carbonate [37]
and calcium oxalate [41,42]. Hunter and co-workers [38] found that modification of OPN's
glutamic acid and aspartic acid residues reduces its inhibitory potency [38]. Constant
composition studies, which measured seeded crystal growth, indicate that aspartic acid is a more
effective inhibitor than glutamic acid [38]. It has also been demonstrated that the inhibition of
crystal formation and growth by OPN involves an interaction between the contiguous aspartic
acid segment of OPN and an array of lattice ions on the surface of the HA crystal [43,50].
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Grohe et al. found that phosphate groups had a significant role in bringing the peptide close to
the crystal surface. They simulated three forms of the same OPN peptide (P0, P1, P3), which
have the same amino acid sequence but different numbers of phosphorylations, interacting with a
calcium oxalate monohydrate (COM) crystal face. They suggested that the adsorption of acidic
peptides to the {100} face of these biominerals is governed by electrostatics and is not dependent
on the particular amino-acid sequence [30]. Another group performed simulations on
phosphorylated OPN peptides in the presence of calcium oxalate, and also concluded that
phosphate groups are involved in the inhibition of crystal growth [46]. Therefore, phosphate
groups increase the electronegativity of OPN, causing a strong interaction with positively
charged crystal face.
Phosphorylation plays a key role in OPN's mineral-modulating activity, with phosphorylated
OPN or its related peptides being much more inhibitory than the non-phosphorylated
recombinant peptides [38,45,46].
More recently de Bruyn et al. applied dynamic light scattering to characterize the effects of
proteins on mineral formation. To evaluate the effect of PTMs, three isoforms of OPN – nOPN,
rOPN and phosphorylated rOPN (p-rOPN) – were examined. Their investigation showed that
both nOPN and p-rOPN inhibit the nucleation of particles from supersaturated calcium
phosphate solutions. On the other hand, rOPN, which lacks the phosphorylations of nOPN, acted
as an inhibitor of HA growth but not the nucleation [75].
Although phosphorylation of OPN seems to be essential to its capability to prevent mineral
growth, it is not clear whether phosphorylation at particular sites in the protein is needed. In this
thesis, we addressed this issue by testing some OPN-derived peptides for their effect on HA
formation and growth. There is some overlap with the work done by de Bruyn and co-workers
[75], and in such cases our results are in good agreement with theirs.
The growth rate of the precipitating crystals in the presence of nOPN and rOPN are plotted as a
function of protein concentration in Figure 5.1. A straight line was fitted to the hydrodynamic
radius data from each run at the time when the hydrodynamic radius was 200 nm. The growth
rate increases with [nOPN], while rOPN causes it to decrease. The decrease in growth rate,
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combined with the absence of a delay in precipitation, suggests that rOPN inhibits the growth,
but not the nucleation of HA crystals.

Figure 5. 1: Growth rate as a function of concentration for nOPN and rOPN at

.

̅

5.2 Quantitative Comparison of Peptides

The experiments were performed on different days with slightly different concentrations. To
compare the results obtained for the different OPN-related peptides, the data for the
hydrodynamic radius of precipitating particles were normalized over time with respect to the
control data. The control data were fitted to a cubic polynomial. Figure 5.2 (A) shows ̅ data
from a typical control run with the fitted polynomial. The deviations of the data from the fit are
illustrated in Figure 5.2 (B). For normalization, the hydrodynamic radius from the peptide run is
divided by the fitted value of ̅ for the control at the same time.
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Figure 5. 2: (A) Typical data for the hydrodynamic radius in a control run. The red line is a fit to a cubic
polynomial. (B) The deviations of the data from the fit.

To compare the inhibitory effects of OPN-related peptides, their hydrodynamic radius data were
normalized as described, then averaged over time.
Figures 5.3 (A) and (B) show the mean normalized hydrodynamic radius as a function of
concentration for P0 and P3 respectively. At low concentrations, P0 has no discernible effect on
the growth of the HA crystals, but the normalized hydrodynamic radius decreases in the presence
of a high concentration of P0.
Increasing the concentration of P3 decreases the hydrodynamic radius substantially. At a
concentration of 5 μg/ml, P0 does not have a measurable effect on the mean normalized
hydrodynamic radius over the forty-minute incubation, while the same concentration of P3
results in a 15% decrease in the mean normalized hydrodynamic radius. This indicates that the
three phosphate groups on P3 play a major role in the inhibition of HA growth.
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Figure 5. 3: Mean normalized hydrodynamic radius as a function of concentration for A) P0 and B) P3.

The growth rate of the precipitating crystals in the presence of P0 and P3 is plotted as a function
of concentration in Figure 5.4. The growth rate was determined by fitting a straight line to the
hydrodynamic radius data for each run at the time when the hydrodynamic radius was 200 nm.
The growth rate for both peptides decreases with increasing concentration, but the effect is much
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more pronounced for P3. This result also indicates that the three phosphates on the P3 peptide
increase its inhibition potency relative to that of P0.

Figure 5. 4: Growth rate as a function of concentration for P0 and P3 at
̅

.

The mean normalized hydrodynamic radius for OPAR and pOPAR are plotted versus
concentration in Figures 5.5 (A) and (B) respectively. These two peptides, which differ only by
the phosphate group on pOPAR, both moderately inhibit the growth of HA crystals at
concentrations up to 2 μg/ml. At higher concentrations of OPAR, the mean value of the
normalized hydrodynamic radius increases back to the control value. This behaviour is not
understood but suggests that the inhibitory potency of OPAR is somehow neutralized at high
concentrations.
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Figure 5. 5: Mean normalized hydrodynamic radius as a function of concentration for A) OPAR and B)
pOPAR.

Figure 5.6 shows the same data for both peptides at low concentrations. Up to 2 μg/ml both
peptides have roughly the same inhibitory effect on HA growth but the mean normalized
hydrodynamic radius is slightly smaller for pOPAR. This suggests that the aspartic acid groups
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in both peptides cause inhibition, but also that the extra phosphate on the pOPAR increases its
inhibitory effect.

Figure 5. 6: Mean normalized hydrodynamic radius as a function of concentration for OPAR and pOPAR.

The growth rate as a function of concentration for OPAR and pOPAR is plotted in Figure 5.7.
Both OPAR and pOPAR decrease the growth rate of HA crystals. At concentrations up to
2 μg/ml the two peptides have approximately the same effect in reducing the growth rate, but the
growth rate in the presence of pOPAR is consistently slightly lower. This result again suggests
that the 11 aspartic acid residues in the two peptides prevent HA crystals from growing and that
the additional phosphate in pOPAR increases its inhibition potency.
The role of phosphate groups in the interaction between OPN-related peptides and biominerals
has been studied using molecular dynamics (MD) simulations. These simulations have
investigated the interaction of peptides with the surface of hydroxyapatite [39] as well as with
calcium oxalate monohydrate (COM, CaC2O4.H2O) which is also found in kidney stones [30].
The OPN-related peptides we studied are negatively charged and are attracted to the Ca2+-rich
{100} faces of HA and COM. More potent inhibitors are attracted more closely to the {100}
faces of both HA and COM [30,39]. The simulations of Azzopardi et al. [39] and Grohe et al.
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[30] suggested that the adsorption of acidic peptides to the {100} face of these biominerals is
governed by electrostatics and is not dependent on the particular amino-acid sequence.

Figure 5. 7: Growth rate as a function of concentration for OPAR and pOPAR P3 at
̅

.

The analysis of Azzopardi et al. suggested that the adsorption strength is inversely related to the
isoelectric point, PI, of the peptide. The PI is the pH value at which the molecule carries no net
electrical charge. Azzopardi et al. found in their simulations that the peptides which approached
the {100} face of HA closely were those with the lowest PI. In other words, more inhibitory
peptides have lower isoelectric points than less inhibitory peptides. They calculated PI for four
virtual peptides: OPAR, pOPAR, P0, and P3, which is shown in Table 5.1.
Azzopardi's simulations showed that pOPAR, which includes the poly aspartic acid sequence of
OPN, formed the closest contact with the {100} face of HA. In addition to the aspartic acids, the
single phosphoserine approached the {100} face most closely.
Atomic scale molecular dynamics simulations performed by Grohe et al. found that the triplyphosphorylated peptide P3, absorbed to the {100} crystal face of COM much more rapidly than
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the singly-phosphorylated P1. They concluded that the phosphates on the phosphoserines drove
the peptide close to the COM crystal face, leading to the more effective inhibition of crystal
growth. Of interest, the authors noted that the acidic amino acid residues in P3 were found closer
to the crystal face than the phosphates.
The inhibition of HA growth by pOPAR, OPAR, P3 and P0 has also been studied by the constant
composition seeded growth method by Azzopardi et al. [39]. Based on the effects of these
peptides on the seeded growth of HA, they determined the concentration of a particular peptide
needed to inhibit the crystal growth by half. This is referred to as the IC50 value. A larger IC50
value is indicative of less inhibitory strength. Their results are summarized in Table 5.1 [39].
The work of Azzopardi et al. and Grohe et al. indicated that P0 has weak inhibitory activity. Our
results on P0 are in good agreement with theirs [30,39]. Table 5.1 compares our DLS results with
those of Azzopardi et al. Based on the DLS results, the order of the inhibitory effect on HA

growth at 2 μg/ml peptide concentrations is pOPAR>OPAR>P3>P0. Measurements were not
done on P0 at 2 μg/ml, but based on data at higher concentration its inhibitory effect is expected
to be less than that of P3. Grohe's simulations established the order of inhibitory potency on
COM crystals for the OPN-derived peptides that they studied to be P3>P1>P0.
Table 5.1 indicates a small difference in the PI values of OPAR and pOPAR, which implies that
both have similar inhibitory potency due to the presence of the aspartic acid residues. Our DLS
results confirm that inhibitory potency increased with the addition of one phosphate group. We
showed that OPAR prevents HA formation, while phosphorylation of OPAR in addition to
inhibiting the nucleation of HA causes a decrease in crystal growth. This explanation is also true
for P3. Having three extra phosphates enhanced the inhibitory potency of P3 over that of P0.
Based on the constant composition (CC) seeded HA growth, IC50 value, and the calculated PI
value,

the

order

of

inhibitory

potency

for

the

OPN-derived

peptides

to

be

P3>pOPAR>OPAR>P0. Although the position of P3 in this sequence is different in our results
from in those of Azzopardi et al., both studies show that phosphorylations play a key role in
inhibition potency of peptides.

68

Table 5. 1: Inhibitory potency of OPN peptides, adopted from [39] and DLS results.

Peptide

PI
value

IC50

Growth rate (nm/s) for

Mean normalized hydrodynamic

(μg/ml)

2 μg/ml inhibitors

radius (nm) for 2 μg/ml inhibitors

(CC)

(DLS)

(DLS)

P3

2.92

1.48

0.200

0.910

pOPAR

3.39

1.93

0.180

0.840

OPAR

3.60

2.97

0.186

0.870

P0

4.17

>75

0.308 (at 5 µg/ml)

1.029 (at 5 µg/ml)

The DLS and the constant-composition experiments are different, so it is difficult to compare
them directly. In the DLS experiment, the composition of the solution varies as new crystals
nucleate and grow, while in the constant-composition experiment the composition of the solution
is kept fixed as pre-existing seed crystals grow. Although the constant-composition assay is not
able to investigate nucleation or the early stages of crystal growth, the work of Azzopardi et al.
indicates the inhibiting potency is more pronounced for the phosphorylated peptides, which is
fully consistent with our DLS results.

5.3 Bone sialoportein

Based on previous observations [20,47], it was postulated that BSP would cause the spontaneous
nucleation of crystals below the normal threshold concentrations of calcium and phosphate ions.
We therefore studied the effect of adding rBSP to solutions with different concentrations of
calcium and phosphate ions.
First we tried to find a concentration of calcium and phosphate ions at which precipitation of
crystals does not happen in the absence of rBSP, but did happen in the presence of rBSP. A
solution of 5.20 mM Ca2+ and 3.25 mM PO43- was chosen. Since in this case the scattered light
intensity is very low, the data are noisy. The count rate is quite small but did increase slightly
over time, indicating that some crystals precipitated. Therefore, if indeed there is a threshold for
the precipitation of particles, the chosen ion concentrations are still slightly above it. The second
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solution contained higher calcium and phosphate ion concentrations, 5.40 mM Ca2+ and
3.37 mM PO43-, and significant precipitation did occur in the absence of rBSP.
For the first case, our DLS results suggested that rBSP may enhance nucleation at very low
concentrations, but appears to inhibit growth at concentrations higher than 2 µg/ml.
For the second solution, the results show a delay in the increase of ̅ for protein concentrations
exceeding 1 μg/ml. Unlike the case of lower ion concentration, here the presence of rBSP delays
the nucleation of the particles, and the delay time becomes larger as the concentration increases.
The observed behaviour of rBSP in the solution with higher ion concentrations is similar to that
observed for OPN in this work, and for p-rOPN in [75]. However, this inhibitory effect is less
significant than that observed with OPN. Furthermore, our data at the higher ion concentrations
suggest that there are more small particles in the presence of the protein than in the control
experiment, suggesting that rBSP promotes the nucleation of HA crystals. It is of interest that
with both rBSP and nOPN, the growth rate of the HA crystals is enhanced. It is postulated that
since BSP and OPN have a high affinity for HA crystals, they will gradually be removed from
the solution as the crystals form. Once this happens, the few crystals can grow at a faster rate
than that seen in control solutions because of the increased availability of calcium and phosphate
ions to drive growth [75].
Previous studies [20,47] have shown that BSP nucleates HA formation in agarose gel and solidphase collagen. Nucleation of HA precipitation by BSP was first observed in steady-state agarose
gel experiments in 1993 [20]. Hunter and Goldberg observed the formation of HA in a gel
containing BSP under conditions of sub-threshold calcium and phosphate saturation. Their
studies suggested that the glutamic acid-rich sequences of BSP played a key role in the
nucleation of HA crystals [20]. The chemical nature of the BSP-collagen interaction was
investigated by Baht et al. in 2008 [47]. It was found that hydrophobic interactions were
responsible for the binding of BSP to collagen and, based on previous studies [61], electrostatic
forces appear to stabilize the interaction. In contrast, other proteins, such as dentin
phosphophoryn and dentin matrix protein-1, bind to collagen electrostatically [47]. The acidic
amino-acid-rich regions of these proteins are involved in collagen binding. It has been shown
that the nucleation potency of BSP increases 10-fold when it is incubated in collagen as
compared to agarose [47].
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Hunter et al. in 1996 reported that in solution studies, BSP at concentrations up to 10 μg/ml had
no effect on hydroxyapatite formation [22]. BSP and its peptides were shown to have an
inhibitory effect of on crystal growth by Stubbs et al. [68]. In their system, which used a seeded
HA crystal assay, native BSP and one of its major fragments were able to suppress crystal
growth. They found that recombinant BSP could also block the growth of HA seeded crystals
suspended in supersaturated solution of calcium and phosphate, but was not as potent as the
native protein. This suggests that post translational modifications contribute to the ability of BSP
to inhibit crystal growth [68].
Goldberg et al. in 1996 suggested that although PTMs are not necessary for nucleation of BSP,
lack of these modifications decrease the potency of the protein [58]. Tye et al. in 2003 compared
the nucleating activity of nBSP and rBSP. Their results were in good agreement with those of
Goldberg et al., and showed that the nucleation activity of BSP resides in two glutamic acid
domains [50].
Molecular dynamics simulations on BSP-derived peptides suggest that the particular sequence of
amino acids is not the only factor that determines the nucleation potency of the peptide, but that
the peptide structure is also important [65].
The effect of dentin phosphophoryn (DPP) on hydroxyapatite formation and growth has been
studied in an in vitro gelatin gel diffusion system [85]. At high concentrations of DPP
(100 μg/ml), the de novo formation of HA decreases, while low concentrations of protein (0.0101 μg/ml) promoted de novo hydroxyapatite formation. These data suggest that DPP has a
multifunctional role in the mineralization process [85]. DPP attached to agarose beads or
collagen has also been shown to promote HA formation [86-89]. Thus it appears the formation of
HA is promoted by immobilized DPP and hindered by high concentrations of DPP in solution.
This appears to be similar to the behavior we observed for BSP, although more experimental
work is needed to confirm this.
Our results in general agree with the previously published studies on BSP and HA formation,
although nucleation potency was not readily apparent by DLS. Additional effort is required to
develop the most appropriate protocol for studying mineral nucleation. However, it is also
possible that BSP does not nucleate well or at all in solution. The previously published studies
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showing BSP-mediated nucleation of hydroxyapatite were done in steady-state agarose or
collagen-gel systems, suggesting that confinement or constraints on the protein conformation
may play a role.
There is good evidence in the literature to support BSP-mediated inhibition of crystal growth.
Our results are also in general agreement with this. Overall, the scattered intensity due to
precipitating calcium phosphate is decreased by the addition of BSP, and while some crystals do
become large, it appears that the majority do not. It would be of interest to determine if further
addition of BSP, for example 20 minutes into a run, would affect the growth of these crystals.
Overall, it seems that the behaviour of BSP is more complicated than the other proteins. We did
not observe unambiguous nucleation under the experimental conditions we investigated.
However there do seem to be similarities between our observations for BSP and what others
have seen for DPP [85]. Many questions remain and substantial additional studies are needed to
clarify the behaviour of BSP.
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Chapter 6: Conclusions and Future Work
6.1 Conclusions
Improved understanding of the effect of modulatory proteins on the crystallization of
hydroxyapatite could eventually lead to the development of drugs or bone repair therapies to
control pathological calcifications resulting from the breakdown of the body’s natural
biomineralization regulatory system.
Dynamic light scattering has proven to be a versatile and convenient method to monitor the
formation process of HA. DLS data provide information about the size distribution of the HA
crystals and their concentrations in aqueous solutions that is not available from other techniques.
This technique allows us to distinguish the effects of proteins and peptides on nucleation and
growth separately. DLS provides an alternative approach to constant composition and steady
state assays for examining the effects of bone-related proteins or synthetic peptides on the
in vitro formation of HA.
We used DLS to measure the time evolution of the particle size distribution and average
scattered light intensity of HA crystals in the presence of proteins and peptides at particular ionic
concentration and pH conditions.
We found that native OPN inhibits the nucleation of HA crystals, while the non-phosphorylated
rOPN strongly inhibits their growth. This confirms that phosphorylation of OPN is critical for
the inhibition of nucleation, while the acidic amino acid groups alone can inhibit crystal growth.
We also studied the inhibitory effects of some synthetic OPN-related peptides. Our results show
that P0 exhibits a very weak inhibitory effect on the growth of HA crystals, while P3, with three
phosphate groups added to the same amino acid sequence, is a potent inhibitor of HA nucleation.
The peptide OPAR is found to moderately inhibit nucleation. On the other hand, the
phosphorylated version of OPAR not only reduced the number of calcium-phosphate particles
but also slightly slowed their growth. Overall, we found the order of inhibitory potency of the
four OPN-derived peptides to be pOPAR>OPAR>P3>P0.
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Our results for rBSP showed that for sub-threshold concentrations of calcium and phosphate it
appears to function as a nucleator at lower protein concentrations, and very likely as an inhibitor
of crystal growth at higher concentrations of protein.

6.2 Future Work

We tried to investigate the nucleation potency of BSP using DLS, but had little success.
Additional effort is required to find the appropriate working concentrations of calcium and
phosphate for studying the nucleation process and the question of whether BSP enhances
mineralization from a solution. Additional study is also needed to determine whether the action
of BSP is different in solution than it is in a gel, and if so, to understand the reasons for the
difference.
Since acidic proteins become nucleators of HA when immobilized, it would be intriguing to
attempt DLS experiments using BSP and OPN covalently linked to agarose beads.
If a protocol for a DLS-based nucleation assay can be established, DLS could be used to
investigate the effects of BSP-derived peptides, the roles of PTMs in BSP, the effects of altering
the poly-Glu sequences of BSP, and the effects of other protein modulators of biominerals.
Our investigations have shown that several proteins and peptides are effective in inhibiting HA
nucleation or growth. It would be of interest to analyze the effect of mixtures of different
inhibitors using DLS.
It would be useful to characterize the morphology of the crystal structures and precipitant at
different stages of growth using XRD. Stopping crystal formation at early times and analyzing
the crystals with XRD would provide insight in to the nature of the precipitating particles and the
process by which HA crystals form in these solutions [70].
All of our DLS experiments to date have been performed at room temperature. Since the
solubility of the calcium phosphate decreases as the temperature is lowered, performing DLS
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experiments at physiological temperature would be a good idea. In addition, experiments as a
function of temperature may provide an alternate way to investigate nucleation and inhibition.
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Laboratories:

Appendix
The twenty essential amino acids. The residues are shown in uncharged state. The three-letter
and one-letter abbreviations are given below the chemical structure of each amino acid [91].
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